We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Technology 14.31%
3 Communication Services 13.23%
4 Financials 10.05%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARYBU
151
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
-402,523
Closed -$4.43M
IMMU
152
DELISTED
Immunomedics Inc
IMMU
-5,860,000
Closed -$498M
HZNP
153
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-150,000
Closed -$11.7M

Similar funds

Thomas Steyer's Q4 2020 Portfolio in Review

As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
  • Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.